BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Mehnert JM, Mitchell TC, Huang AC, Aleman TS, Kim BJ, Schuchter LM, Linette GP, Karakousis GC, Mitnick S, Giles L, Carberry M, Frey N, Kossenkov A, Groisberg R, Hernandez-Aya LF, Ansstas G, Silk AW, Chandra S, Sosman JA, Gimotty PA, Mick R, Amaravadi RK.
Mehnert JM, et al. Among authors: silk aw.
Clin Cancer Res. 2022 Mar 15;28(6):1098-1106. doi: 10.1158/1078-0432.CCR-21-3382.
Clin Cancer Res. 2022.
PMID: 35022320
Free PMC article.
Clinical Trial.